Treating chronic noninfectious posterior segment uveitis

The impact of cumulative damage: Proceedings of an expert panel roundtable discussion

Quan Dong Nguyen, David Callanan, Pravin Dugel, David G. Godfrey, Debra A. Goldstein, Jacob T. Wilensky

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Chronic noninfectious posterior segment uveitis refers to inflammation of the retina, choroid, vitreous, or optic nerve, and may result in permanent vision loss. The inflammation can be constant, or characterized by periodic exacerbations on an underlying baseline of inflammation. Recent studies indicate that this vision loss often results from cumulative damage over multiple recurrences of inflammation, rather than from a single initiating event. Most forms of local therapy provide only transient suppression of inflammation, and the use of systemic agents may be limited by serious side effects. The course of uveitis may, therefore, be marked by recurrent episodes of inflammation, each contributing to progressive and permanent loss of visual acuity. The goal of uveitis treatment should not only be to suppress inflammation when it recurs but also to attain complete remission of inflammation, and thus prevent complications such as cystoid macular edema (CME) and permanent cumulative damage. The RETISERT intravitreal implant offers sustained local control of inflammation without the systemic side effects that limit standard immunosuppressive and oral corticosteroid therapies. The recommendation of the expert panel was that RETISERT is a useful addition to the armamentarium for the treatment of chronic noninfectious posterior segment uveitis and may help to prevent cumulative damage from repeated occurrences of inflammation, especially when vision can be improved rather than only stabilized.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalRetina
Volume26
Issue number8 SUPPL.
DOIs
StatePublished - Oct 1 2006

Fingerprint

Posterior Uveitis
Inflammation
Uveitis
Macular Edema
Choroid
Therapeutics
Immunosuppressive Agents
Optic Nerve
Visual Acuity
Retina
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Treating chronic noninfectious posterior segment uveitis : The impact of cumulative damage: Proceedings of an expert panel roundtable discussion. / Nguyen, Quan Dong; Callanan, David; Dugel, Pravin; Godfrey, David G.; Goldstein, Debra A.; Wilensky, Jacob T.

In: Retina, Vol. 26, No. 8 SUPPL., 01.10.2006, p. 1-16.

Research output: Contribution to journalArticle

Nguyen, Quan Dong ; Callanan, David ; Dugel, Pravin ; Godfrey, David G. ; Goldstein, Debra A. ; Wilensky, Jacob T. / Treating chronic noninfectious posterior segment uveitis : The impact of cumulative damage: Proceedings of an expert panel roundtable discussion. In: Retina. 2006 ; Vol. 26, No. 8 SUPPL. pp. 1-16.
@article{ff5bb61f18e74b289c9b34e561b795f1,
title = "Treating chronic noninfectious posterior segment uveitis: The impact of cumulative damage: Proceedings of an expert panel roundtable discussion",
abstract = "Chronic noninfectious posterior segment uveitis refers to inflammation of the retina, choroid, vitreous, or optic nerve, and may result in permanent vision loss. The inflammation can be constant, or characterized by periodic exacerbations on an underlying baseline of inflammation. Recent studies indicate that this vision loss often results from cumulative damage over multiple recurrences of inflammation, rather than from a single initiating event. Most forms of local therapy provide only transient suppression of inflammation, and the use of systemic agents may be limited by serious side effects. The course of uveitis may, therefore, be marked by recurrent episodes of inflammation, each contributing to progressive and permanent loss of visual acuity. The goal of uveitis treatment should not only be to suppress inflammation when it recurs but also to attain complete remission of inflammation, and thus prevent complications such as cystoid macular edema (CME) and permanent cumulative damage. The RETISERT intravitreal implant offers sustained local control of inflammation without the systemic side effects that limit standard immunosuppressive and oral corticosteroid therapies. The recommendation of the expert panel was that RETISERT is a useful addition to the armamentarium for the treatment of chronic noninfectious posterior segment uveitis and may help to prevent cumulative damage from repeated occurrences of inflammation, especially when vision can be improved rather than only stabilized.",
author = "Nguyen, {Quan Dong} and David Callanan and Pravin Dugel and Godfrey, {David G.} and Goldstein, {Debra A.} and Wilensky, {Jacob T.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1097/01.iae.0000250601.15893.5f",
language = "English (US)",
volume = "26",
pages = "1--16",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Treating chronic noninfectious posterior segment uveitis

T2 - The impact of cumulative damage: Proceedings of an expert panel roundtable discussion

AU - Nguyen, Quan Dong

AU - Callanan, David

AU - Dugel, Pravin

AU - Godfrey, David G.

AU - Goldstein, Debra A.

AU - Wilensky, Jacob T.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Chronic noninfectious posterior segment uveitis refers to inflammation of the retina, choroid, vitreous, or optic nerve, and may result in permanent vision loss. The inflammation can be constant, or characterized by periodic exacerbations on an underlying baseline of inflammation. Recent studies indicate that this vision loss often results from cumulative damage over multiple recurrences of inflammation, rather than from a single initiating event. Most forms of local therapy provide only transient suppression of inflammation, and the use of systemic agents may be limited by serious side effects. The course of uveitis may, therefore, be marked by recurrent episodes of inflammation, each contributing to progressive and permanent loss of visual acuity. The goal of uveitis treatment should not only be to suppress inflammation when it recurs but also to attain complete remission of inflammation, and thus prevent complications such as cystoid macular edema (CME) and permanent cumulative damage. The RETISERT intravitreal implant offers sustained local control of inflammation without the systemic side effects that limit standard immunosuppressive and oral corticosteroid therapies. The recommendation of the expert panel was that RETISERT is a useful addition to the armamentarium for the treatment of chronic noninfectious posterior segment uveitis and may help to prevent cumulative damage from repeated occurrences of inflammation, especially when vision can be improved rather than only stabilized.

AB - Chronic noninfectious posterior segment uveitis refers to inflammation of the retina, choroid, vitreous, or optic nerve, and may result in permanent vision loss. The inflammation can be constant, or characterized by periodic exacerbations on an underlying baseline of inflammation. Recent studies indicate that this vision loss often results from cumulative damage over multiple recurrences of inflammation, rather than from a single initiating event. Most forms of local therapy provide only transient suppression of inflammation, and the use of systemic agents may be limited by serious side effects. The course of uveitis may, therefore, be marked by recurrent episodes of inflammation, each contributing to progressive and permanent loss of visual acuity. The goal of uveitis treatment should not only be to suppress inflammation when it recurs but also to attain complete remission of inflammation, and thus prevent complications such as cystoid macular edema (CME) and permanent cumulative damage. The RETISERT intravitreal implant offers sustained local control of inflammation without the systemic side effects that limit standard immunosuppressive and oral corticosteroid therapies. The recommendation of the expert panel was that RETISERT is a useful addition to the armamentarium for the treatment of chronic noninfectious posterior segment uveitis and may help to prevent cumulative damage from repeated occurrences of inflammation, especially when vision can be improved rather than only stabilized.

UR - http://www.scopus.com/inward/record.url?scp=33750297437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750297437&partnerID=8YFLogxK

U2 - 10.1097/01.iae.0000250601.15893.5f

DO - 10.1097/01.iae.0000250601.15893.5f

M3 - Article

VL - 26

SP - 1

EP - 16

JO - Retina

JF - Retina

SN - 0275-004X

IS - 8 SUPPL.

ER -